Literature DB >> 34580087

Diabetes and the Risk of Long-term Post-COVID Symptoms.

César Fernández-de-Las-Peñas1, Carlos Guijarro2,3, Juan Torres-Macho4,5, María Velasco-Arribas3,6, Susana Plaza-Canteli7,8, Valentín Hernández-Barrera9, José A Arias-Navalón8.   

Abstract

This study investigated the association of diabetes in patients who recovered from severe acute respiratory syndrome coronavirus 2 infection with the presence of long-term post-coronavirus disease (COVID) symptoms. A case-control study that included individuals hospitalized during the first wave of the pandemic was conducted. Patients with a previous diagnosis of diabetes and under medical control were considered case subjects. Two age- and sex-matched patients without presenting diabetes per case subject were recruited as control subjects. Hospitalization and clinical data were collected from hospital medical records. Patients were scheduled for a telephone interview. A list of post-COVID symptoms was systematically evaluated, but participants were invited to freely report any symptom. The Hospital Anxiety and Depression Scale and the Pittsburgh Sleep Quality Index were used to assess anxiety and depressive symptoms, and sleep quality, respectively. Multivariable conditional logistic regression models were constructed. Overall, 145 patients with diabetes and 144 control subjects without diabetes who had recovered from COVID-19 were assessed at 7.2 (SD 0.6) months after hospital discharge. The number of post-COVID symptoms was similar between groups (incident rate ratio 1.06, 95% CI 0.92-1.24, P = 0.372). The most prevalent post-COVID symptoms were fatigue, dyspnea on exertion, and pain. No between-groups differences in any post-COVID symptom were observed. Similarly, no differences in limitations with daily living activities were found between patients with and without diabetes. Diabetes was not a risk factor for experiencing long-term post-COVID symptoms.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2021        PMID: 34580087     DOI: 10.2337/db21-0329

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?

Authors:  Olga V Saik; Vadim V Klimontov
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Clustering analysis reveals different profiles associating long-term post-COVID symptoms, COVID-19 symptoms at hospital admission and previous medical co-morbidities in previously hospitalized COVID-19 survivors.

Authors:  César Fernández-de-Las-Peñas; José D Martín-Guerrero; Lidiane L Florencio; Esperanza Navarro-Pardo; Jorge Rodríguez-Jiménez; Juan Torres-Macho; Oscar J Pellicer-Valero
Journal:  Infection       Date:  2022-04-22       Impact factor: 7.455

3.  Post-acute sequelae of COVID-19: A metabolic perspective.

Authors:  Philipp E Scherer; John P Kirwan; Clifford J Rosen
Journal:  Elife       Date:  2022-03-23       Impact factor: 8.140

4.  Prediabetes Induces More Severe Acute COVID-19 Associated With IL-6 Production Without Worsening Long-Term Symptoms.

Authors:  Icaro Bonyek-Silva; Thiago Cerqueira-Silva; Sara Nunes; Antônio Fernando Araújo Machado; Márcio Rivison Silva Cruz; Blenda Pereira; Leilane Estrela; Jéssica Silva; Ananda Isis; Aldina Barral; Pablo Rafael Silveira Oliveira; Ricardo Khouri; C Henrique Serezani; Cláudia Brodskyn; Juliana Ribeiro Caldas; Manoel Barral-Netto; Viviane Boaventura; Natalia Machado Tavares
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-08       Impact factor: 6.055

5.  Long-COVID, Metabolic and Endocrine Disease.

Authors:  Stefan R Bornstein; Diana Cozma; Margrit Kamel; Mawieh Hamad; Mohammad G Mohammad; Naveed A Khan; Maha M Saber; Mohammad H Semreen; Charlotte Steenblock
Journal:  Horm Metab Res       Date:  2022-06-20       Impact factor: 2.788

6.  Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system.

Authors:  Arneaux Kruger; Mare Vlok; Simone Turner; Chantelle Venter; Gert Jacobus Laubscher; Douglas B Kell; Etheresia Pretorius
Journal:  Cardiovasc Diabetol       Date:  2022-09-21       Impact factor: 8.949

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.